The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells

Issam Ben Sahra, Jean François Tanti, Frédéric Bost*

*Corresponding author for this work

Research output: Contribution to journalShort surveypeer-review

81 Scopus citations

Abstract

Targeting cancer cell metabolism is a promising new strategy to fight cancer. Metformin, a widely used antidiabetic agent, and 2-deoxyglucose (2DG) drastically affect cancer cell metabolism. Recently, we showed that the combination of the two drugs was much more harmful for cancer cells than the treatment with metformin or 2DG alone. At the cellular level, this combination leads to p53- and AMPK-dependent apoptosis. Furthermore, we showed that metformin inhibits 2DG-induced autophagy, decreases beclin 1 expression and triggers a switch from a survival process to cell death.

Original languageEnglish (US)
Pages (from-to)670-671
Number of pages2
JournalAutophagy
Volume6
Issue number5
DOIs
StatePublished - Jul 1 2010

Keywords

  • 2 deoxyglucose
  • AMPK
  • Apoptosis
  • Autophagy
  • Metabolism
  • Metformin
  • P53
  • Prostate cancer

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'The combination of metformin and 2-deoxyglucose inhibits autophagy and induces AMPK-dependent apoptosis in prostate cancer cells'. Together they form a unique fingerprint.

Cite this